



NEWS UPDATE

Date: 16/07/2025

Centre Fixes Prices of 71 Key Drug Formulations, Including Cancer Medicines



The Centre, through the National Pharmaceutical Pricing Authority (NPPA), has fixed the retail prices of 71 essential drug formulations under the Drug (Prices Control) Order, 2013. This move focuses on enhancing affordability and accessibility of vital medications, including treatments for cancer, diabetes, peptic ulcers, and infections. Notably, the price of Trastuzumab, a monoclonal antibody used in metastatic breast cancer, has been capped at approximately ₹11,966.64 per vial, while a suspension of mefenamic acid for menstrual pain is fixed at ₹0.94 per ml. Additionally, anti-diabetic combinations containing Empagliflozin are now priced between ₹14–₹31 per tablet, ensuring critical diabetes medications remain within reach.

Under the notification, manufacturers may include GST in the MRP only if it has been paid or is payable. Pharmacies are required to display the revised prices prominently for consumer awareness. This policy aligns with broader NPPA efforts under the DPCO framework to regulate scheduled drugs and promote fair pricing, reinforcing government priorities for public healthcare and cost containment.

Source: <https://timesofindia.indiatimes.com/india/centre-fixes-prices-of-71-key-drug-formulations-including-cancer-medicines/articleshow/122475241.cms>